The selective estrogen enzyme modulators in breast cancer: a review
The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550 · cited 1×
“The gene was localized on chromosome 17q21 [12,13], but its characterization and use as a marker are still a matter of great controversy (for a review, see Ref.”
BackgroundFerguson, S. S. G. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01478-9 · Cited by 1,826
Multiple hormone interactions in the developmental biology of the mammary gland.
Topper, Y. J., & Freeman, C. S. (1980) · Physiological Reviews · doi:10.1152/physrev.1980.60.4.1049 · Cited by 856 · cited 1×
“During pregnancy, it is suggested that the elevated values of circulating progesterone are responsible for the induction of lobular-alveolar development, to prepare the breast for lactation [135,136].”
BackgroundEstrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture.
Henderson, B. E., Ross, R. K., & Bernstein, L. (1988) · PubMed · Cited by 852
The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology
Labrie, F., Luu-The, V., Lin, S.-X., Claude, L., Simard, J., Breton, R., & Bélanger, A. (1997) · Steroids · doi:10.1016/s0039-128x(96)00174-2 · Cited by 480
van Landeghem, A. A. J., Poortman, J., Nabuurs, M., & Thijssen, J. H. H. (1985) · PubMed · Cited by 448
Pasqualini, J. R. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.4.1460 · Cited by 433
Self-citation4-Hydroxylation of estrogens as marker of human mammary tumors.
Liehr, J. G., & Ricci, M. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3294 · Cited by 414 · cited 1×
“Whether 4-hydroxy estrogens are involved in human carcinogenesis is still unclear, but it is interesting to note that high concentrations of 4-hydroxy estrogens are present in human breast tumors [67].”
BackgroundSANTNER, S. J., FEIL, P. D., & SANTEN, R. J. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-1-29 · Cited by 406 · cited 2×
“Quantitative evaluation indicates that in human breast tumor E1S ‘via sulfatase’ is a much more likely precursor for E2 than is androgens ‘via aromatase’ [17,31].”
BackgroundCellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 397 · cited 1×
“Despite the low levels of circulating estrogens, the tissular concentrations of estrone (E1), estradiol (E2) and their sulfates (E1S, E2S) are several times higher than those found in the plasma or in the area of the breast considered as normal tissue, suggesting a specific tumoral biosynthesis and accumulation of the…”
BackgroundVariant human breast tumor estrogen receptor with constitutive transcriptional activity.
Fuqua, S. A. W., Fitzgerald, S. D., Chamness, G. C., Tandon, A. K., McDonnell, D. P., Nawaz, Z., O’Malley, B. W., & McGuire, W. L. (1991) · PubMed · Cited by 394
Persson, I., Yuen, J., Bergkvist, L., & Schairer, C. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960729)67:3<327::aid-ijc4>3.0.co;2-t · Cited by 334 · cited 1×
“The paradoxical effect of E2 could be related to ERT, a treatment that has been observed to have either no effect or to slightly increase breast cancer incidence [177] but significantly decrease mortality [178–182].”
BackgroundAutocrine and paracrine growth regulation of human breast cancer
Lippman, M. E., Dickson, R. B., Bates, S. E., Knabbe, C., Huff, K. K., Swain, S. M., McManaway, M. E., Bronzert, D. A., Kasid, A., & Gelmann, E. P. (1986) · Breast Cancer Research and Treatment · doi:10.1007/bf01806790 · Cited by 305 · cited 1×
“Most breast cancers (about 95%), whether in pre- or postmenopausal women, are initially hormone-dependent, where the hormone estradiol plays a crucial role in their development and progression [1–4].”
BackgroundA Correlative Morphologic Study of Human Breast and Endometrium in the Menstrual Cycle
Longacre, T. A., & Bartow, S. A. (1986) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198606000-00003 · Cited by 286 · cited 1×
“sponds to the high levels of estradiol and progesterone [134].”
BackgroundIs 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?
Zhu, B. T., & Conney, A. H. (1998) · PubMed · Cited by 276
Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors.
Fuqua, S. A. W., Sd, F., Allred, D. C., Elledge, R. M., Nawaz, Z., Dp, M., O’Malley, B. W., Greene, G., & Wl, M. (1992) · Cancer Research · Cited by 276
2‐Methoxyestradiol, a Promising Anticancer Agent
Lakhani, N. J., Sarkar, M. A., Venitz, J., & Figg, W. D. (2003) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.2.165.32088 · Cited by 274
Estrone Sulfate: Production Rate and Metabolism in Man
Ruder, H. J., Loriaux, L., & Lipsett, M. B. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106862 · Cited by 257 · cited 2×
“, 1972 [48] 0.”
InfluentialVermeulen, A., Deslypere, J. P., Paridaens, R., Leclercq, G., Roy, F., & Heuson, J. C. (1986) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(86)90121-5 · Cited by 254 · cited 1×
“…0.77F 0.021 1.46F 0.43 Prost et al., 1984 [40] 0.81F 0.22 1.77F 0.53 Prost et al., 1984 [40] 0.19–1.36 0.25–4.95 Hawkins et al., 1985 [51] – 0.92–0.80 Vermeulen et al., 1986 [16] – 0.70 Lonning et al., 1989 [52] – – Massobrio et al., 1994 [47] – – Recchione et al., 1995 [53] 0.52F 0.13 0.37F…”
InfluentialImportance of estrogen sulfates in breast cancer
Pasqualini, J. R., Gelly, C., Nguyen, B.-L., & Vella, C. (1989) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(89)90077-0 · Cited by 227 · cited 1×
“1) [23–27].”
Self-citationBacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase
Falany, C. N., Krasnykh, V., & Falany, J. L. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00015-r · Cited by 220 · cited 1×
“This difference between hormone-dependent and hormone-independent cells could reflect the presence of various isoforms of EST or several other STs (such as phenolST or hydroxy-ST) with different kinetic properties, which are also able to conjugate estrogens but at micromolar concentrations [123,130].”
BackgroundEstrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential
Howarth, N. M., Purohit, A., Reed, M. J., & Potter, B. V. L. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00028a002 · Cited by 218 · cited 1×
“Estrone-3-O-sulfamate (EMATE) is a potent synthesized sulfatase inhibitor [90]: at a concentration of 10 7 M the estrone sulfatase activity in MCF-7 cells in inhibited by 99% [91,92].”
BackgroundFISHMAN, J., & MARTUCCI, C. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-611 · Cited by 215 · cited 1×
“16a-Hydroxy estrone has estrogenic activity which, based on the increased uterine weight of ovariectomized rats, is more potent than that of estradiol itself [68].”
BackgroundEstrogen and Progesterone Receptors in Breast Cancer
Yip, C.-H., & Rhodes, A. (2014) · Future Oncology · doi:10.2217/fon.14.110 · Cited by 208
Willis, D. B., Calle, E. E., Miracle-McMahill, H. L., & Heath, C. W. (1996) · Cancer Causes & Control · doi:10.1007/bf00052671 · Cited by 202
STROTT, C. A. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-6-670 · Cited by 200 · cited 1×
“It was demonstrated that a single gene, assigned to chromosome 16, can transcribe at the same time brain phenol sulfotransferase (PST or HAST), M-PST, and human placental EST 1 mRNA by alternate exon 1b and exon 1b promoters, respectively [132].”
BackgroundLaidlaw, I. J. (1995) · Endocrinology · doi:10.1210/en.136.1.164 · Cited by 189
MIETTINEN, M. M., MUSTONEN, M. V. J., POUTANEN, M. H., ISOMAA, V. V., & VIHKO, R. K. (1996) · Biochemical Journal · doi:10.1042/bj3140839 · Cited by 188
BONNEY, R. C., REED, M. J., DAVIDSON, K., BERANEK, P. A., & JAMES, V. H. T. (1983) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1983.tb00051.x · Cited by 187 · cited 1×
“…2.55 Ruder et al., 1972 [48] 0.11F 0.92 – Roberts et al., 1980 [37] 1.30F 0.40 – Towobola et al., 1980 [39] 0.84F 0.49 (0.25–2.62) – Noel et al., 1981 [49] 1.35F 0.23 1.20F 0.22 Samojlik et al., 1982 [38] – – Bonney et al., 1983 [28] 0.87F 0.57 0.83F 0.51 Reed et al., 1983 [50] 1.50F 1.04 1.91F1.”
InfluentialThe measurement of estrone sulfate in plasma
LORIAUX, D., RUDER, H., & LIPSETT, M. (1971) · Steroids · doi:10.1016/0039-128x(71)90059-6 · Cited by 186 · cited 1×
“, 1971 [41] 2.”
GOMPEL, A., MALET, C., SPRITZER, P., LALARDRIE, J.-P., KUTTENN, F., & MAUVAIS-JARVIS, P. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-5-1174 · Cited by 179
Effects of Plasma Estrogen Sulfates in Mammary Cancer Cells*
VIGNON, F., TERQUI, M., WESTLEY, B., DEROCQ, D., & ROCHEFORT, H. (1980) · Endocrinology · doi:10.1210/endo-106-4-1079 · Cited by 178 · cited 1×
“1) [23–27].”
Steroid sulfation by expressed human cytosolic sulfotransferases
Falany, C. N., Wheeler, J., Oh, T. S., & Falany, J. L. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90077-9 · Cited by 177 · cited 3×
“However, in the breast cancer cells the phenol sulfotransferase (P-ST), which is active at micromolar concentrations of E2 (see Schemes 1 and 2), is present and the hEST is not present [33,117,123].”
BackgroundMusgrove, E. A., Lee, C. S., & Sutherland, R. L. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5032 · Cited by 175
Antiestrogenic Effect of R5020, a Synthetic Progestin in Human Breast Cancer Cells in Culture*
Vignon, F., Bardon, S., Chalbos, D., & Rochefort, H. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1124 · Cited by 173
Parenti, G., Meroni, G., & Ballabio, A. (1997) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(97)80153-0 · Cited by 168 · cited 1×
“liver, endometrium, ovaries, bone, brain, prostate, white blood cells, adipocytes) but it is particularly prevalent in the placenta and breast carcinoma tissue [74–76].”
BackgroundPotent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates
Woo, L. W. L., Purohit, A., Malini, B., Reed, M. J., & Potter, B. V. L. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00023-5 · Cited by 168 · cited 1×
“A new interesting family of compounds has been synthesized with a tricyclic coumarin sulfamate structure [99– 103].”
BackgroundFalany, J. L., & Falany, C. N. (1996) · PubMed · Cited by 165
Tibolone: prevention of bone loss in late postmenopausal women
Bjarnason, N. H., Bjarnason, K., Haarbo, J., Rosenquist, C., & Christiansen, C. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.7.8675554 · Cited by 156
Elger, W. A. G., Schwarz, S., Hedden, A., Reddersen, G., & Schneider, B. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00214-6 · Cited by 156 · cited 1×
“Unfortunately, the potent estrogenic activity of this compound precludes its use in clinical applications [93,94].”
BackgroundBartek, J., Bartkova, J., Kyprianou, N., Lalani, E. N., Staskova, Z., Shearer, M., Chang, S., & Taylor-Papadimitriou, J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3520 · Cited by 150
Aromatization of androgens by human breast cancer
Abul‐Hajj, Y. J., Iverson, R., & Kiang, D. T. (1979) · Steroids · doi:10.1016/0039-128x(79)90027-8 · Cited by 149 · cited 1×
“Two principal pathways are implicated in the last steps of E2 formation in breast cancer tissues: the ‘aromatase pathway’ which transforms androgens into estrogens [20–22] and the ‘sulfatase pathway’ which converts E1S into E1 by the estrone sulfatase (EC: 3.”
BackgroundMiyoshi, Y., Ando, A., Shiba, E., Taguchi, T., Tamaki, Y., & Noguchi, S. (2001) · International Journal of Cancer · doi:10.1002/ijc.1525 · Cited by 148 · cited 2×
“[110] suggest that the sulfatase mRNA levels can serve as a significant, independent poor prognostic factor only in ER-positive tumors.”
BackgroundEffects of 17 beta-estradiol metabolites on cell cycle events in MCF-7 cells.
Lottering, M.-L., Haag, M., & Seegers, J. C. (1992) · PubMed · Cited by 142
Horwitz, K. B., & Freidenberg, G. R. (1985) · PubMed · Cited by 137
Human Liver Estrogen Sulfotransferase: Identification by cDNA Cloning and Expression
Aksoy, I. A., Wood, T. C., & Weinshilboum, R. M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1637 · Cited by 136 · cited 1×
“MCF-7, ZR-75-1, T-47D) and is efficient in catalyzing the sulfation of 2-hydroxy-estrone and 2-hydroxy-estradiol, and the hEST-2, which selectively catalyzes sulfonation of estradiol, estrone, and ethinyl estradiol [33,111,112].”
BackgroundAromatase activity in primary and metastatic human breast cancer
Lipton, A., Santner, S. J., Santen, R. J., Harvey, H. A., Feil, P. D., White-Hershey, D., Bartholomew, M. J., & Antle, C. E. (1987) · Cancer · doi:10.1002/1097-0142(19870215)59:4<779::aid-cncr2820590419>3.0.co;2-u · Cited by 135 · cited 1×
“Two principal pathways are implicated in the last steps of E2 formation in breast cancer tissues: the ‘aromatase pathway’ which transforms androgens into estrogens [20–22] and the ‘sulfatase pathway’ which converts E1S into E1 by the estrone sulfatase (EC: 3.”
BackgroundCastles, C. G., Fuqua, S. A. W., Klotz, D. M., & Hill, S. M. (1993) · PubMed · Cited by 132
Suzuki, T., Moriya, T., Ariga, N., Kaneko, C., Kanazawa, M., & Sasano, H. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0956 · Cited by 130
McManus, M. J., & Welsch, C. W. (1984) · Cancer · doi:10.1002/1097-0142(19841101)54:9<1920::aid-cncr2820540924>3.0.co;2-f · Cited by 124
Reed, M. J., Cheng, R. W., Noel, C. T., Dudley, H. A. F., & James, V. H. T. (1983) · PubMed · Cited by 115
Sawicki, M. W., Erman, M., Puranen, T., Vihko, P., & Ghosh, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.3.840 · Cited by 113
Chetrite, G. S., Kloosterboer, H. J., & Pasqualini, J. R. (1997) · PubMed · Cited by 113
Self-citationElevated steroid sulfatase expression in breast cancers
Utsumi, T., Yoshimura, N., Takeuchi, S., MARUTA, M., Maeda, K., & Harada, N. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00060-1 · Cited by 111 · cited 1×
“[109] indicated that the steroid sulfatase mRNA level in breast cancer tissues from 38 patients were significantly increased (1458F 2119 attomols/mg RNA) as compared with non-malignant tissues (535F 663 attomols/mg RNA).”
BackgroundMerriam, G. R., MacLusky, N. J., Picard, M. K., & Naftolin, F. N. (1980) · Steroids · doi:10.1016/0039-128x(80)90062-8 · Cited by 111
Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues
Recchione, C., Venturelli, E., Manzari, A., Cavalleri, A., Martinetti, A., & Secreto, G. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00017-t · Cited by 108 · cited 1×
“…[40] 0.19–1.36 0.25–4.95 Hawkins et al., 1985 [51] – 0.92–0.80 Vermeulen et al., 1986 [16] – 0.70 Lonning et al., 1989 [52] – – Massobrio et al., 1994 [47] – – Recchione et al., 1995 [53] 0.52F 0.13 0.37F 0.19 Pasqualini et al., 1996 [17] This review summarizes the recent…”
InfluentialRecent data on estrogen sulfatases and sulfotransferases activities in human breast cancer
Pasqualini, J. R., Schatz, B., Varin, C., & Nguyen, B. ‐. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90358-p · Cited by 100 · cited 1×
“promegestone) provoke a significant decrease of estradiol formation when physiological concentrations of estrone sulfate are incubated with breast cancer cells (MCF-7 and T-47D) [81–87].”
BackgroundSelf-citationEstrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma
Tseng, L., Mazella, J., Lee, L. Y., & Stone, M. L. (1983) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(83)91116-0 · Cited by 99 · cited 1×
“The presence of sulfotransferases in normal and carcinomous breast is extensively demonstrated [120–122].”
BackgroundPasqualini, J. R., Gelly, C., & Lecerf, F. (1986) · Breast Cancer Research and Treatment · doi:10.1007/bf01807336 · Cited by 97 · cited 1×
“1) [23–27].”
Self-citationStein, R., Dowsett, M., Hedley, A., Gazet, J.-C., Ford, H., & Coombes, R. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.356 · Cited by 96
Purohit, A., Vernon, K. A., Hummelinck, A. E. W., Woo, L. W. L., Hejaz, H. A., Potter, B. V. L., & Reed, M. J. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00196-9 · Cited by 95
Noel, C. T., Reed, M. J., Jacobs, H. S., & James, V. H. T. (1981) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(81)90039-x · Cited by 94 · cited 1×
“…a in pmol/ml) – 1.35F 2.55 Ruder et al., 1972 [48] 0.11F 0.92 – Roberts et al., 1980 [37] 1.30F 0.40 – Towobola et al., 1980 [39] 0.84F 0.49 (0.25–2.62) – Noel et al., 1981 [49] 1.35F 0.23 1.20F 0.22 Samojlik et al., 1982 [38] – – Bonney et al., 1983 [28] 0.87F 0.57 0.83F 0.51 Reed et al., 1983…”
InfluentialMcNeill, J. M., Reed, M. J., Beranek, P. A., Bonney, R. C., Ghilchik, M. W., Robinson, D. J., & James, V. H. T. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910380208 · Cited by 92 · cited 1×
“However, in vivo studies, after isotopic infusion of estrogens to postmenopausal breast cancer patients, have shown that the reductive direction is greater than the oxidative [29].”
BackgroundMacIndoe, J. H., Woods, G. R., Jeffries, L., & Hinkhouse, M. M. (1988) · Endocrinology · doi:10.1210/endo-123-3-1281 · Cited by 91
Structure−Activity Relationships of 17α-Derivatives of Estradiol as Inhibitors of Steroid Sulfatase
Boivin, R. P., Luu-The, V., Lachance, R., Labrie, F., & Poirier, D. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0001166 · Cited by 86
The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells
Lippert, C., Seeger, H., & Mueck, A. O. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02305-6 · Cited by 85 · cited 1×
“It is interesting that 2-methoxy estradiol can inhibit the proliferation of breast cancer cells [60,61].”
BackgroundHAWKINS, R. A., & OAKEY, R. E. (1974) · Journal of Endocrinology · doi:10.1677/joe.0.0600003 · Cited by 85
Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates
Malini, B., Purohit, A., Ganeshapillai, D., Woo, L. W. L., Potter, B. V. L., & Reed, M. J. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00178-3 · Cited by 85
Antioestrogens in the management of hormone-dependent cancer
Litherland, S. A., & Jackson, I. M. (1988) · Cancer Treatment Reviews · doi:10.1016/0305-7372(88)90002-3 · Cited by 83
de Jong, P. C., van de Ven, J., Nortier, H. W., Maitimu-Smeele, I., Donker, T. H., Thijssen, J. H. H., Slee, P. H. T. J., & Blankenstein, R. A. (1997) · PubMed · Cited by 82
Jernström, H., Frenander, J., Fernö, M., & Olsson, H. L. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690543 · Cited by 82 · cited 1×
“The paradoxical effect of E2 could be related to ERT, a treatment that has been observed to have either no effect or to slightly increase breast cancer incidence [177] but significantly decrease mortality [178–182].”
BackgroundEstradiol metabolism and malignant disease
Mueck, A. O., Seeger, H., & Lippert, T. H. (2002) · Maturitas · doi:10.1016/s0378-5122(02)00141-x · Cited by 80 · cited 1×
“4-Hydroxy estrone and 4-hydroxy estradiol possess estrogenic properties and exert a stimulatory effect on the growth of MCF-7 breast cancer cells [64,65].”
BackgroundProst, O., TURREL, M. O., Dahan, N., Craveur, C., & Adessi, G. (1984) · PubMed · Cited by 79
Steroid Sulfatase Activities in Human Breast Tumors
Dao, T. L., Hayes, C. L., & Libby, P. R. (1974) · Experimental Biology and Medicine · doi:10.3181/00379727-146-38109 · Cited by 78 · cited 1×
“1) [23–27].”
Tremblay, M. R., & Poirier, D. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00043-0 · Cited by 78
POUTANEN, M. H., Moncharmont, B., & Vihko, R. (1992) · PubMed · Cited by 77
Catecholestrogens are MCF-7 cell estrogen receptor agonists
Schütze, N., Vollmer, G., Tiemann, I., Geiger, M., & Knüppen, R. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90319-r · Cited by 76
Purohit, A., Williams, G. J., Roberts, C. J., Potter, B. V. L., & Reed, M. J. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630119 · Cited by 76 · cited 1×
“Estrone-3-O-sulfamate (EMATE) is a potent synthesized sulfatase inhibitor [90]: at a concentration of 10 7 M the estrone sulfatase activity in MCF-7 cells in inhibited by 99% [91,92].”
BackgroundSAMOJLIK, E., Santen, R. J., & Worgul, T. J. (1982) · Steroids · doi:10.1016/0039-128x(82)90050-2 · Cited by 75 · cited 2×
“…2.55 Ruder et al., 1972 [48] 0.11F 0.92 – Roberts et al., 1980 [37] 1.30F 0.40 – Towobola et al., 1980 [39] 0.84F 0.49 (0.25–2.62) – Noel et al., 1981 [49] 1.35F 0.23 1.20F 0.22 Samojlik et al., 1982 [38] – – Bonney et al., 1983 [28] 0.87F 0.57 0.83F 0.51 Reed et al., 1983 [50] 1.50F 1.04 1.91F1.”
BackgroundInfluentialPollow, K., BOQUOI, E., Baumann, J., Schmidt‐Gollwitzer, M., & Pollow, B. (1977) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(77)90108-3 · Cited by 75
Ciobanu, L. C., Boivin, R. P., Luu-The, V., Labrie, F., & Poirier, D. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980677l · Cited by 74
Abnormal estrogen receptor in clinical breast cancer
McGuire, W. L., Chamness, G. C., & Fuqua, S. A. W. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90214-4 · Cited by 74 · cited 1×
“17h-HSD-1 = 17h deletions and truncations appear in the receptor gene [7–9]; the ER becomes ‘non-functional’ and, despite the estrogen binding, the cell fails to respond to the hormone.”
Background17β‐hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue
Miettinen, M., Mustonen, M. V. J., POUTANEN, M. H., ISOMAA, V. V., Wickman, M., Söderqvist, G., Vihko, R., & Vihko, P. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006217400137 · Cited by 73
Woo, L. W. L., Lightowler, M., Purohit, A., Reed, M. J., & Potter, B. V. L. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00244-8 · Cited by 73
Plasma estrone sulfate levels in postmenopausal women
Roberts, K. D., Rochefort, J. G., Bleau, G., & Chapdelaine, A. (1980) · Steroids · doi:10.1016/0039-128x(80)90101-4 · Cited by 72 · cited 2×
“During the menstrual cycle [35,36] and in postmenopausal women [37,38] estrone sulfate (E1S) levels are 5–10 times those of unconjugated estrogens (estrone, estradiol, and estriol).”
BackgroundInfluentialThe relationship between breast cancer survival and prior postmenopausal estrogen use.
Strickland, D., Gambrell, R. D., Butzin, C. A., & Strickland, K. (1992) · PubMed · Cited by 72
The selective estrogen enzyme modulator (SEEM) in breast cancer
Chetrite, G. S., & Pasqualini, J. R. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00046-2 · Cited by 71
Self-citationEvidence for involvement of BRCA1 in sporadic breast carcinomas.
Cropp, C. S., Nevanlinna, H. A., Pyrhönen, S. O., Stenman, U., Salmikangas, P., Albertsen, H., White, R. L., & Callahan, R. (1994) · PubMed · Cited by 69
Qian, Y., Deng, C., & Song, W.-C. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37617-7 · Cited by 68 · cited 2×
“[118] demonstrated that the restoration of EST expression in MCF-7 cells by cDNA transfection could significantly attenuate the response on both gene activity and DNA synthesis, and cell numbers were used as markers of estrogen-stimulated cell growth and proliferation.”
BackgroundMethodLongman, S. M., & Buehring, G. C. (1987) · Cancer · doi:10.1002/1097-0142(19870115)59:2<281::aid-cncr2820590218>3.0.co;2-a · Cited by 68
Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues
Thijssen, J. H. H., & Blankenstein, M. A. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90377-5 · Cited by 67 · cited 1×
“60 – – Thijssen and Blankenstein, 1989 [56] 1.”
A Specific Radioimmunoassay for Estrone Sulfate in Plasma and Urine without Hydrolysis*
Wright, K. R., Collins, D. C., MUSEY, P. I., & Preedy, J. R. K. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-47-5-1092 · Cited by 67
Regulation of estrogen activity by sulfation in human MCF-7 breast cancer cells.
Falany, J. L., & Falany, C. N. (1997) · PubMed · Cited by 66
Kalkhoven, E., Isbrücker, L., de Laat, S. W., van der Saag, P. T., & van der Burg, B. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90096-5 · Cited by 65
(2008) · CRC Press eBooks · doi:10.3109/9781420058734 · Cited by 64
Bonnier, P., Bessenay, F., Sasco, A. J., Beedassy, B., Lejeune, C., Romain, S., Charpin, C., Piana, L., & Martin, P. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(199806)79:3 · Cited by 63 · cited 1×
“The paradoxical effect of E2 could be related to ERT, a treatment that has been observed to have either no effect or to slightly increase breast cancer incidence [177] but significantly decrease mortality [178–182].”
BackgroundRegulation of steroid sulphatase expression and activity in breast cancer
Newman, S. P., Purohit, A., Ghilchik, M. W., Potter, B. V. L., & Reed, M. J. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00177-1 · Cited by 62 · cited 1×
“[108] observed no effect of the cytokine tumor necrosis factor-a (TNF-a) or of interleukin (IL-6) on mRNA sulfatase expression in MCF-7 cells.”
BackgroundInhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens
Santner, S. J., & Santen, R. J. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90007-j · Cited by 62
MALET, C., GOMPEL, A., YANEVA, H., CREN, H., FIDJI, N., MOWSZOWICZ, I., KUTTENN, F., & MAUVAIS-JARVIS, P. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-1-8 · Cited by 61
Chetrite, G. S., Hj, K., Philippe, J. C., & Pasqualini, J. R. (1999) · PubMed · Cited by 61
Self-citationLønning, P. E., Johannessen, D. C., & Thorsen, T. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.231 · Cited by 61 · cited 1×
“, 1989 [52] – – Massobrio et al.”
Adams, E. F., Coldham, N. G., & James, V. H. T. (1988) · Journal of Endocrinology · doi:10.1677/joe.0.1180149 · Cited by 60
(1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)90010-2 · Cited by 59
Couture, P. (1993) · Endocrinology · doi:10.1210/en.132.1.179 · Cited by 54
Botella, J., Duranti, E., Duc, I., Cognet, A. M., Delansorne, R., & Paris, J. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90170-8 · Cited by 53 · cited 1×
“The proliferative effect of progestins using various isolated breast cancer models: cell lines, organ culture, or transplantation of breast cancer cells in nude mice, is contradictory as it was reported that these compound can either inhibit [142–145], stimulate [146–148], or have no effect [149].”
BackgroundAromatase inhibitors and the treatment of breast cancer
Brodie, A. M., Wing, L.-Y., Goss, P. E., Dowsett, M., & Coombes, R. C. (1986) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(86)90037-3 · Cited by 50
Coldham, N. G., & James, V. H. T. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450131 · Cited by 50
Non-steroidal and steroidal sulfamates: new drugs for cancer therapy
Purohit, A., Woo, L. W. L., Barrow, D., Hejaz, H. A., Nicholson, R. I., Potter, B. V. L., & Reed, M. J. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00428-7 · Cited by 49
Catherino, W. H., & Jordan, V. C. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00171-u · Cited by 49
Nguyen, B. ‐., Chetrite, G., & Pasqualini, J. R. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00665786 · Cited by 49
Self-citationPlasma hormones in pre- and postmenopausal breast cancer
Drafta, D., Schindler, A. E., Milcu, S. M., Keller, E., Stroe, E., Horodniceanu, E., & Bălănescu, I. (1980) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(80)90231-9 · Cited by 49 · cited 1×
“, 1980 [43] – – Drafta et al.”
Poutanen, M., Isomaa, V., Kainulainen, K., & Vihko, R. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910460524 · Cited by 48
Chetrite, G. S., Paris, J., Botella, J., & Pasqualini, J. R. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(96)00094-5 · Cited by 48
Self-citationde Jong, P. C., van de Ven, J., Nortier, J. W. R., Maitimu-Smeele, I., Denker, G. H., Thijssen, J. H. H., Slee, P. H. T. J., & Blankenstein, M. A. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)84407-3 · Cited by 46 · cited 1×
“At present, the positive effect of anti-aromatase compounds on the benefit in breast cancer patients is well documented [72,73].”
Background17-Beta-Hydroxysteroid Dehydrogenase in Human Breast and Endometrial Carcinoma
Sasano, H., Suzuki, T., Takeyama, J., Utsunomiya, H., Ito, K., Ariga, N., & Moriya, T. (2000) · Oncology · doi:10.1159/000055281 · Cited by 46
The Role of Hormones in the Development of Human Breast Cancer
Kirschner, M. A. (1979) · Springer eBooks · doi:10.1007/978-1-4899-2663-0_6 · Cited by 46 · cited 1×
“Most breast cancers (about 95%), whether in pre- or postmenopausal women, are initially hormone-dependent, where the hormone estradiol plays a crucial role in their development and progression [1–4].”
Background(1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)90000-x · Cited by 46
Steroid Sulfatase Activity in Osteoblast Cells
Fujikawa, H., Okura, F., Kuwano, Y., Sekizawa, A., Chiba, H., Shimodaira, K., Saito, H., & Yanaihara, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.6038 · Cited by 44 · cited 1×
“liver, endometrium, ovaries, bone, brain, prostate, white blood cells, adipocytes) but it is particularly prevalent in the placenta and breast carcinoma tissue [74–76].”
BackgroundChetrite, G. S., Ebert, C., Wright, F., Philippe, A.-C., & Pasqualini, J. R. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00095-3 · Cited by 44 · cited 1×
“promegestone) provoke a significant decrease of estradiol formation when physiological concentrations of estrone sulfate are incubated with breast cancer cells (MCF-7 and T-47D) [81–87].”
BackgroundSelf-citationBernier, F., Leblanc, G., Labrie, F., & Luu-The, V (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46914-1 · Cited by 43
WITH THE TECHNICAL ASSISTANCE OF .
Gertrudis, S. (1959) · Cited by 43
Control and expression of oestrone sulphatase activities in human breast cancer
Pasqualini, J. R., Chetrite, G. S., & Nestour, E. L. (1996) · Journal of Endocrinology · doi:10.1677/joe.0.150s099 · Cited by 43 · cited 2×
“…[51] – 0.92–0.80 Vermeulen et al., 1986 [16] – 0.70 Lonning et al., 1989 [52] – – Massobrio et al., 1994 [47] – – Recchione et al., 1995 [53] 0.52F 0.13 0.37F 0.19 Pasqualini et al., 1996 [17] This review summarizes the recent information concerning the enzymes and their control, involved in…”
BackgroundInfluentialSelf-citation17α-Alkyl- or 17α-substituted benzyl-17β-estradiols: A new family of estrone-sulfatase inhibitors
Poirier, D., & Boivin, R. P. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00330-8 · Cited by 43
Hormones and Mammary Carcinogenesis
Segaloff, A. (1978) · Springer eBooks · doi:10.1007/978-1-4757-4673-0_1 · Cited by 43 · cited 1×
“Most breast cancers (about 95%), whether in pre- or postmenopausal women, are initially hormone-dependent, where the hormone estradiol plays a crucial role in their development and progression [1–4].”
BackgroundMiettinen, M., POUTANEN, M. H., & Vihko, R. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961127)68:5<600::aid-ijc8>3.0.co;2-2 · Cited by 42
Anderson, C., Lucas, L. H., & Widlanski, T. S. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00118a034 · Cited by 41
Malet, C., Spritzer, P. M., Guillaumin, D., et al. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00061-3 · Cited by 41
(1991) · Elsevier eBooks · doi:10.1016/c2009-0-00786-7 · Cited by 40
Expression and regulation of 17β-hydroxysteroid dehydrogenase type 1
Peltoketo, H., ISOMAA, V. V., POUTANEN, M. H., & Vihko, R. (1996) · Journal of Endocrinology · doi:10.1677/joe.0.150s021 · Cited by 39
Pasqualini, J. R., Maloche, C., Maroni, M., & Chetrite, G. S. (1994) · PubMed · Cited by 39
Self-citationFalany, J. L., Lawing, L. F., & Falany, C. N. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90102-3 · Cited by 38 · cited 1×
“hP-PST has an affinity for estrogen sulfation about 300-fold lower than that of hEST [119,123].”
BackgroundCatechol-O-methyltransferase in human breast cancers
Assicot, M., Contesso, G., & Bohuon, C. (1977) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(77)90173-6 · Cited by 38
Estradiol 17 beta-hydroxysteroid dehydrogenase, a marker of breast cancer hormone dependency.
Fournier, S., Brihmat, F., Durand, J., Sterkers, N., Martin, P., Kuttenn, F., & MAUVAIS-JARVIS, P. (1985) · PubMed · Cited by 37
Regulation of cell cycle and cyclins by 16alpha-hydroxyestrone in MCF-7 breast cancer cells
Lewis, J., Thomas, T. J., Klinge, C. M., Gallo, M., & Thomas, T. (2001) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0270293 · Cited by 37 · cited 1×
“[71] showed in MCF-7 breast cancer cells that this estrogen is capable of accelerating cell cycle kinetics and stimulating the expression of cell cycle regulatory proteins.”
BackgroundParadoxical effect of estradiol: it can block its own bioformation in human breast cancer cells
Pasqualini, J. R., & Chetrite, G. S. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00080-2 · Cited by 37 · cited 2×
“Recent studies have demonstrated a paradoxical effect of E2 in MCF-7 and T-47D breast cancer cells in that it can block its own bioformation by inhibiting, in a dose-dependent manner, the conversion of E1S to E2 in the range of concentrations from 5 10 10 to 5 10 5 M [104] (Fig.”
BackgroundSelf-citationOestrone sulphate, adipose tissue, and breast cancer
Hawkins, R. A., Thomson, M. L., & Killen, E. (1985) · Breast Cancer Research and Treatment · doi:10.1007/bf01806013 · Cited by 36 · cited 1×
“06 Prost et al., 1984 [40] 0.77F 0.021 1.46F 0.43 Prost et al., 1984 [40] 0.81F 0.22 1.77F 0.53 Prost et al., 1984 [40] 0.19–1.36 0.25–4.95 Hawkins et al., 1985 [51] – 0.92–0.80 Vermeulen et al., 1986 [16] – 0.70 Lonning et al., 1989 [52] – – Massobrio et al., 1994 [47] – – Recchione et al., 1995…”
InfluentialPersistent estrogen responsiveness of ras oncogene-transformed mouse mammary epithelial cells
Suto, A., Bradlow, H. L., Wong, G. Y., Osborne, M. P., & TELANG, N. T. (1992) · Steroids · doi:10.1016/0039-128x(92)90058-h · Cited by 36 · cited 1×
“It was suggested that 16a-hydroxy estrone could be implicated in carcinogenesis, for instance a comparison of the E2 metabolism of murine mammary epithelial cells revealed that 16a-hydroxylation was significantly elevated in high-risk animals [69,70].”
BackgroundHughes, P., TWIST, L. E., Durham, J. N., Choudhry, M. A., Drayson, M. T., Chandraratna, R. A. S., Michell, R. H., KIRK, C. J., & Brown, G. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3550361 · Cited by 34
Steroid sulphotransferase activity in human hormone-independent MDA-MB-468 mammary cancer cells
Pasqualini, J. R. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90110-n · Cited by 33 · cited 1×
“It is also well established that steroid sulfotransferases (ST), which convert estrogens into their sulfates, are also present in breast cancer tissues [32,33].”
BackgroundSelf-citationPelletier, J. D., Labrie, F., & Poirier, D. (1994) · Steroids · doi:10.1016/0039-128x(94)90072-8 · Cited by 33
Ariga, N., Moriya, T., Suzuki, T., Kimura, M., Ohuchi, N., Satomi, S., & Sasano, H. (2000) · PubMed · Cited by 32
Metabolism of estradiol by human breast cancer
Abul‐Hajj, Y. J., Thijssen, J. H. H., & Blankenstein, M. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90124-1 · Cited by 32 · cited 1×
“The conversion of E1 and E2 to C2-hydroxy derivatives in breast cancer tissues and the subsequent formation of catechol O-methyl estrogen by the action of an O-methyltransferase is well documented [57–59].”
BackgroundSuzuki, T., Sasano, H., Andersson, S., & Mason, J. I. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6918 · Cited by 31
Chetrite, G. S., Nestour, E. L., & Pasqualini, J. R. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00063-6 · Cited by 31
Self-citationPasqualini, J. R., & Nguyen, B. ‐. (1991) · Breast Cancer Research and Treatment · doi:10.1007/bf01980971 · Cited by 30
Self-citation17β-estradiol dehydrogenase (E2DH) activity in T47D cells
Malet, C., Vacca, A., Kuttenn, F., & MAUVAIS-JARVIS, P. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90378-i · Cited by 29
Differential effects of progestins on breast tissue enzymes
Pasqualini, J. R. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.018 · Cited by 28 · cited 1×
“promegestone) provoke a significant decrease of estradiol formation when physiological concentrations of estrone sulfate are incubated with breast cancer cells (MCF-7 and T-47D) [81–87].”
BackgroundSelf-citationBreast Cancer: Prognosis, Treatment and Prevention
(2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00195-4 · Cited by 26
Oestrogen sulphotransferases in malignant and normal human breast tissue
Anderson, E., & Howell, A. (1995) · Endocrine Related Cancer · doi:10.1677/erc.0.0020227 · Cited by 25 · cited 2×
“This study was confirmed by Anderson and Howell [114] using two normal breast epithelial cells: the MTSV 1–7 and the MRSV 4–4 produced by SV 40 immortalization cells obtained from human milk [115].”
ResultProperties of estrogen and hydroxysteroid sulphotransferases in human mammary cancer
Adams, J. B., & Phillips, N. S. (1990) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(90)90190-4 · Cited by 22 · cited 1×
“The presence of sulfotransferases in normal and carcinomous breast is extensively demonstrated [120–122].”
BackgroundSchatz, R. W., Soto, A. M., & Sonnenschein, C. (1985) · Journal of Cellular Physiology · doi:10.1002/jcp.1041240305 · Cited by 22
Chetrite, G. S., Ebert, C., Wright, F., Philippe, J.-C., & Pasqualini, J. R. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00163-0 · Cited by 20
Self-citationSharp, S., Anderson, J. M., & Coughtrie, M. W. H. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00244-y · Cited by 20 · cited 1×
“The presence of sulfotransferases in normal and carcinomous breast is extensively demonstrated [120–122].”
BackgroundAntiestrogen action in mammary cancer and in fetal cells
Pasqualini, J. R., Giambiagi, N., Gelly, C., & Chetrite, G. S. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90483-2 · Cited by 19 · cited 1×
“The anti-estrogen tamoxifen and its more important metabolite 4-hydroxytamoxifen, as well as ICI 164,384, have been reported to be inhibitors of sulfatase activity, probably through a non-competitive mechanism [77–80].”
BackgroundSelf-citationTOWOBOLA, O. A., CRILLY, R. C., & OAKEY, R. E. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb03412.x · Cited by 18 · cited 3×
“, 1980 [39] 0.”
BackgroundInfluentialSuzuki, T. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3669 · Cited by 17
Steroid sulfatase inhibitor alters blood pressure and steroid profiles in hypertensive rats
Valigora, S. D., Li, P., Dunphy, G., Turner, M. E., & Ely, D. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00062-5 · Cited by 12 · cited 1×
“Unfortunately, the potent estrogenic activity of this compound precludes its use in clinical applications [93,94].”
BackgroundMassobrio, M., Migliardi, M., Cassoni, P., Menzaghi, C., Revelli, A., & Cenderelli, G. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90091-4 · Cited by 10 · cited 1×
“…1.77F 0.53 Prost et al., 1984 [40] 0.19–1.36 0.25–4.95 Hawkins et al., 1985 [51] – 0.92–0.80 Vermeulen et al., 1986 [16] – 0.70 Lonning et al., 1989 [52] – – Massobrio et al., 1994 [47] – – Recchione et al., 1995 [53] 0.52F 0.13 0.37F 0.19 Pasqualini et al., 1996 [17] This review summarizes the…”
InfluentialThe Selective Estrogen Enzyme Modulators (SEEM) in Breast Cancer
Chetrite, G. S. (2002) · CRC Press eBooks · doi:10.1201/b14039-8 · Cited by 9
High metabolization of catecholestrogens by type 1 estrogen sulfotransferase (hEST1)
Faucher, F., Lacoste, L., Dufort, I., & Luu-The, V. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00025-5 · Cited by 9
Estrogen and Progesterone Receptors in Breast Cancer
Hopp, T. A., & Fuqua, S. A. W. (2003) · Elsevier eBooks · doi:10.1016/b0-12-341103-3/00086-3 · Cited by 7
Aromatase Inhibitors and Their Application to the Treatment of Breast Cancer
Brodie, A. M. H. (2002) · CRC Press eBooks · doi:10.3109/9780203909249-11 · Cited by 5 · cited 1×
“A series of reviews has been published recently on the biological effects and the therapeutic applications of these anti-aromatases [22,175,176].”
BackgroundMechanisms Involved in Carcinogenesis of the Breast
Russo, J. (2002) · CRC Press eBooks · doi:10.3109/9780203909249-4 · Cited by 5 · cited 1×
“During pregnancy, it is suggested that the elevated values of circulating progesterone are responsible for the induction of lobular-alveolar development, to prepare the breast for lactation [135,136].”
BackgroundPasqualini, J. R., Cortés-Prieto, J., Chetrite, G. S., Talbi, M., & Ruiz, A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970317)70:6<639::aid-ijc2>3.0.co;2-w
Self-citation
Cited by
Mechanisms of cancer inhibition by melatonin
Reiter, R. J. (2004) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2004.00165.x · Cited by 223
Current status on development of steroids as anticancer agents
Gupta, A., Sathish Kumar, B., & Negi, A. S. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.05.011 · Cited by 216
Sex steroid-producing enzymes in human breast cancer
Suzuki, T., Miki, Y., Nakamura, Y., Moriya, T., Ito, K., Ohuchi, N., & Sasano, H. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00834 · Cited by 182
“In hormone-dependent breast cancer cell lines, such as MCF7, T47D, R-27, and ZR75-1, 17bHSD1 was the predominant reductive isoform, while oxidative 17bHSD activity was the preferential enzymatic orientation in hormone-independent breast cancer cell lines such as MDA-MB-231, NDA-MB-436, and Hs-578S (Pasqualini 2004).”
BackgroundInfluentialPasqualini, J. R. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.08.004 · Cited by 141
Self-citationTorres-Santiago, L., Mericq, V., Taboada, M., Unanue, N., Klein, K. O., Singh, R., Hossain, J., Santen, R. J., Ross, J. L., & Mauras, N. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4243 · Cited by 99
“These precursors serve as an estrogen reservoir that can be converted back to estradiol in peripheral tissue (17).”
Background
Metadata
- Authors
- Pasqualini, J. R.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2004-06
- Volume
- 1654
- Issue
- 2
- Pages
- 123-143
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W2076977446
- Cited by
- 192
- References
- 164
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.